The Next Generation of Validated Protein Degradation

• Optimizing physical chemical properties for more favourable ADME characteristics of TACs
• Leveraging PROTACs as binders for antibodies, as well as payloads
• Discussing rationally designing candidates that break out of the structural constraints of E3 ligases

Speakers:

Eric Chou

Translational Medicines Associate Director

AnHorn Medicines

Jon Bernardini

CEO

Proxima Bio

Hyunsun Jo

Chief Executive Officer

Pin Therapeutics

Chang Hoon Ji

Executive Director

AUTOTAC Bio